Nelson B. Moseley Ii

Array ( [id] => 12023683 [patent_doc_number] => 20170313783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'ANTIBODIES THAT SPECIFICALLY BIND TO TIM3' [patent_app_type] => utility [patent_app_number] => 15/462538 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 25146 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18643302 [patent_doc_number] => 11767362 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-09-26 [patent_title] => Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies [patent_app_type] => utility [patent_app_number] => 16/084346 [patent_app_country] => US [patent_app_date] => 2017-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 37416 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999483 [patent_doc_number] => 11078274 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Siglec neutralizing antibodies [patent_app_type] => utility [patent_app_number] => 16/082959 [patent_app_country] => US [patent_app_date] => 2017-03-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 38733 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 345 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16082959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15604221 [patent_doc_number] => 10583151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-10 [patent_title] => Polymalic acid-based nanobiopolymer compositions [patent_app_type] => utility [patent_app_number] => 15/447439 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 13 [patent_no_of_words] => 17556 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15447439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15071077 [patent_doc_number] => 10465014 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => PDL-1 antibody, pharmaceutical composition thereof, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/745230 [patent_app_country] => US [patent_app_date] => 2017-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 30 [patent_no_of_words] => 14203 [patent_no_of_claims] => 64 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15745230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957937 [patent_doc_number] => 20190055312 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => BINDING MEMBERS TO PD-L1 [patent_app_type] => utility [patent_app_number] => 16/079210 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23403 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11662651 [patent_doc_number] => 20170151356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases' [patent_app_type] => utility [patent_app_number] => 15/432278 [patent_app_country] => US [patent_app_date] => 2017-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 44225 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15432278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11850344 [patent_doc_number] => 20170224837 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS' [patent_app_type] => utility [patent_app_number] => 15/429671 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 67271 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15429671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451566 [patent_doc_number] => 20230192844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/074600 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16074600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13748827 [patent_doc_number] => 10167345 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Antigen binding formats for use in therapeutic treatments or diagnostic assays [patent_app_type] => utility [patent_app_number] => 15/421559 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11352 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 143 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15421559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11727892 [patent_doc_number] => 20170189335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'DOSAGE AND ADMINISTRATION FOR PREVENTING CARDIOTOXICITY IN TREATMENT WITH ERBB2-TARGETED IMMUNOLIPOSOMES COMPRISING ANTHRACYCLINE CHEMOTHERAPEUTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 15/409238 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 11242 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15409238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15163343 [patent_doc_number] => 10487152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => IgE antibodies for the inhibition of tumor metastasis [patent_app_type] => utility [patent_app_number] => 15/405723 [patent_app_country] => US [patent_app_date] => 2017-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13493 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 155 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15405723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11647924 [patent_doc_number] => 20170143825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS' [patent_app_type] => utility [patent_app_number] => 15/402662 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30342 [patent_no_of_claims] => 106 [patent_no_of_ind_claims] => 48 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15402662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058999 [patent_doc_number] => 11938193 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Compositions comprising chemerin and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/068890 [patent_app_country] => US [patent_app_date] => 2017-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 98 [patent_no_of_words] => 23759 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17306336 [patent_doc_number] => 11207419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment [patent_app_type] => utility [patent_app_number] => 16/068665 [patent_app_country] => US [patent_app_date] => 2017-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 32 [patent_no_of_words] => 12112 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14210733 [patent_doc_number] => 20190117751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => TUMOR ANTIGEN PEPTIDE [patent_app_type] => utility [patent_app_number] => 16/065488 [patent_app_country] => US [patent_app_date] => 2016-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11936493 [patent_doc_number] => 20170240643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-24 [patent_title] => 'INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE AND OTHER CANCER CELLS' [patent_app_type] => utility [patent_app_number] => 15/390378 [patent_app_country] => US [patent_app_date] => 2016-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 30699 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15390378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11568636 [patent_doc_number] => 20170107281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'ANG2-BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 15/386181 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 83 [patent_figures_cnt] => 83 [patent_no_of_words] => 28085 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821873 [patent_doc_number] => 20170210810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'BIOMARKER PROFILES FOR PREDICTING OUTCOMES OF CANCER THERAPY WITH ERBB3 INHIBITORS AND/OR CHEMOTHERAPIES' [patent_app_type] => utility [patent_app_number] => 15/386723 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 26718 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706281 [patent_doc_number] => 20170174779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'Combination of Anti-PD-1 Antibodies and Anti-CD20/Anti-CD3 Antibodies to Treat Cancer' [patent_app_type] => utility [patent_app_number] => 15/386453 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21398 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386453 [rel_patent_id] =>[rel_patent_doc_number] =>)